Company intelligence / Profile preview

CSPC Megalith Biopharmaceutical Co., Ltd.

Shijiazhuang, Hebei, Chinaprnewswire.com ↗

Ownership: Private
Employees: ~600
Development stage: Phase 1

Overview

The company has multiple approved products and a robust pipeline with several candidates in late-stage development. SYS6010 received Breakthrough Therapy Designation from China's NMPA for EGFR mutation-positive advanced non-small cell lung cancer. CRB-701 (SYS6002) is in Phase I trials for advanced solid tumors.

Therapeutic areas: OncologyDermatologyCardiovascularNeurology
Modalities: Monoclonal antibodiesAntibody drug conjugates (ADCs)BiosimilarsSmall molecule drugsProphylactic vaccines
Industry: Biotech

Drug pipeline

11 assets

SYS6043

10 more assets in the full pipeline.

Request access →

Partnerships

Corbus Pharmaceuticals (for CRB-701/SYS6002)Radiance Biopharma (for SYS6005)

Beyond the preview

Go deeper on CSPC Megalith Biopharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CSPC Megalith Biopharmaceutical Co., Ltd..

Explore the full profile